Publications

Publications

At Bayer, we are working in collaboration with the leading scientific, academic, and community partners to improve our understanding of cardiorenal diseases.  

 

We invite you to explore Bayer-supported publications pertaining to chronic kidney disease associated with type 2 diabetes. This library is not intended to serve as a comprehensive repository of all publications. Publications not supported by Bayer are not included. Access to the full text of publications may depend on journal access rights.

 

To help narrow down your search, choose the relevant tags and click apply. Applying multiple tags will narrow your results.

 

Last updated: November 25, 2025

Types of Enhancements Available

audio
Audio
infographic
Graphical Abstract
PLS
Plain Language Summary
video
Video
other
Others

To help narrow down your search, select the relevant filters from the dropdowns and Click Apply

Hold down Ctrl key on keyboard to select multiple years

Total available publications: 220    

Filtered results: 220

Addressing unmet needs for chronic kidney disease treatment in type 1 diabetes: A review

Tuttle KR., et al, Diabetes Obes Metab. 2025

Tuttle KR, 31 10 2025

Dosing, treatment patterns, and safety of finerenone use in routine care: an interim analysis of the prospective, real-world, and observational FINE-REAL study

Wheeler DC., et al, Clinical Kidney Journal. 2025

Wheeler DC, 31 10 2025

Post hoc analyses of DKD clinical trials in ethnic minorities (asian, hispanic, black): A narrative review

Hsiao L., et al, Clinical Therapeutics. 2025

Hsiao L, 31 10 2025

Risk of progression and costs of care for patients with type 2 diabetes and chronic kidney disease

Tangri N., et al, Diabetes Therapy. 2025

Tangri N, 31 10 2025

The challenges of using electronic medical records (EMR) to facilitate guideline-directed medical therapy (GDMT) for patients with heart failure (HF) and chronic kidney disease (CKD)

Desai N., et al, Heart Failure Reviews. 2025

Desai NR, 31 10 2025

Comparing CKD populations with T1D and T2D: a perspective based on the FINE-ONE and FIDELITY populations

Heerspink HJL., Nephrology Dialysis Transplantation. 2025

Heerspink HJL, 30 09 2025

Effect of finerenone on morbidity and mortality in CKD

Ostrominski JW., et al, JASN. 2025

Ostrominski JW, 30 09 2025

Impact of baseline GLP-1 receptor agonist use on albuminuria reduction and safety with simultaneous initiation of finerenone and empagliflozin in type 2 diabetes and chronic kidney disease (CONFIDENCE Trial)

Agarwal R., et al, Diabetes Care. 2025

Agarwal R, 30 09 2025

Impact of simultaneous initiation of finerenone and empagliflozin on urinary albumin-to-creatinine ratio in Asia

Agarwal R., et al, CJASN. 2025

Agarwal R, 30 09 2025

Incident heart failure in adults with mild to moderate chronic kidney disease

Girouard MP., et al, JACC: Heart Failure. 2025

Girouard MP, 30 09 2025